Current status of the therapy of advanced renal carcinoma.
A preclinical murine renal model system is available for evaluation of the effectiveness of therapeutic agents. Clinical review reveals that objective response rates to hormonal agents reported since 1971 have been substantially lower than those reported prior to 1971. Many chemotherapeutic agents have not been adequately evaluated clinically or with the experimental model. Vinblastine to date may be the most active single agent with a 25% objective response rate. At the present time, it is uncertain whether combination chemotherapy or hormonal chemotherapy add to response rates obtained with single agents. There is some evidence that immunotherapy may be of some adjuvant benefit and, thus may provide an additional avenue of investigation.
D000230:Adenocarcinoma / Q000628:therapy*; D000728:Androgens / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000628:therapy*; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009365:Neoplasm Regression, Spontaneous; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011372:Progestins / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012673:Semustine / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use
D000728:Androgens; D000970:Antineoplastic Agents; D011372:Progestins; D012673:Semustine; D014747:Vinblastine; D008130:Lomustine